

*Joint Meeting*



2<sup>nd</sup> World Congress on

## **Bioavailability & Bioequivalence:**

Pharmaceutical R & D Summit-2011

International Conference on

## **Pharmaceutics & Novel Drug Delivery Systems**

06-08 June 2011 Las Vegas, USA

# *Programme*

### **Conference Secretariat**

#### **BABE-2011 & Pharmaceutica-2011**

5716 Corsa Ave., Suite 110, Westlake, Los Angeles, CA 91362-7354, USA

Phone: +1- 650-268-9744, Fax: +1-650-618-1414, Toll free: +1-800-216-6499

E-mail: [babe2011@omicsonline.biz](mailto:babe2011@omicsonline.biz) & [pharmaceutica2011@omicsonline.org](mailto:pharmaceutica2011@omicsonline.org)

# Programme 6-8 June 2011

6 June 11

## Rennissance II & III

07:30-09:30 Registrations

10:00-11:00 Opening Ceremony

Coffee Break: 11:00-11:15

### Keynote Forum

11:15-11:20 Introduction

11:20-11:40 Dr. Barbara M Davit, Center for Drug Evaluation and Research-FDA, USA

11:40-12:00 Dr. Michael Retsky, Harvard School of Public Health, USA

12:00-12:20 Dr. Henry Yunhui Wu, Merck Research Laboratories, USA

12:20-12:40 Dr. Cheng Wang, National Center for Toxicological Research-FDA, USA

12:40-13:00 Dr. Mak Jawadekar, Pfizer Inc.-Connecticut, USA

Lunch: 13:00-13:30

13:30-13:50 Dr. Dale P Conner, Center for Drug Evaluation and Research-FDA, USA

13:50-14:10 Dr. Jian Li, Monash University, Australia

14:10-14:30 Dr. Sid BhoopaAthy, Absorption Systems, USA

14:30-14:50 Dr. Ethan M Stier, Center for Drug Evaluation and Research-FDA, USA

14:50-15:10 Dr. Chyung S. Cook, Baxter Healthcare, USA

15:10-15:30 Dr. Maryse Picher, Zintro Inc., USA

Coffee Break: 15:30-15:45

Track 1 (i): Drug Design, Development and Therapy  
Track 1 (ii): New Strategies for Drug Development  
Track 1 (iii): Epidemiology of Drug Interactions: Biochemical Mechanisms of Drug Toxicity  
Track 1 (v): CNS Drug Development: Principles, Transport Kinetics, Diseases & Methods

Session Introduction

15:45 - 16:05 **Title: Challenges and opportunities of antibacterial drug discovery**  
**Dr. Bolin Geng**, AstraZeneca R&D Boston, USA

16:05 - 16:25 **Title: Targeting cancer stem cells: Challenges and opportunities**  
**Dr. Xiaoyan Jiang**, University of British Columbia, Canada

16:25 - 16:45 **Title: Potential neurotoxic effects of anesthetics during development and potential protective agents**  
**Dr. Cheng Wang**, National Center for Toxicological Research-FDA, USA

16:45 - 17:05 **Title: Single-dose, bioequivalence, rate of absorption, and food effect study of a new Paracetamol/Caffeine formulation in healthy volunteers**  
**Dr. Dongzhou J. Liu**, GlaxoSmithKline, USA

17:05 - 17:25

**Title: New drug screening strategy for infectious diseases: The power of common sense**

**Dr. Maryse Picher**, Cystic Fibrosis/Pulmonary Research and Treatment Center, USA

17:25 - 17:45

**Title: Design, synthesis and anti-HBV activity of L-amino acid ester pro-drugs of acyclic nucleoside phosphonates**

**Dr. FU Xiao zhong**, Guiyang Medical College, China

17:45 - 18:05

**Title: Self-nanoemulsifying drug delivery system of Amisulpride: Optimization of formulation variables using central composite design**

**Dr. Ahmed A. Aboelwafa**, Cairo University, Egypt

18:05 - 18:25

**Title: Turkey disposal and recycling for drug industry**

**Dr. Ayse BAYRAK**, Scientific and Technical Research Council of Turkey, Turkey

18:25 - 18:45

**Title: Viral ion channels in drug discovery**

**Dr. Wolfgang B. Fischer**, National Yang-Ming University, Taiwan

Capital Room

B2B

15:45 - 18:00

7 June 11

Capital Room

Track 3(i): Advances in Mass Spectrometry Methodology Development and Pharmaceutical Applications  
Track 3(ii): Evaluation of Bioequivalence of Highly Variable Drugs and Drug Products

Session Introduction

08:00 - 08:20

**Title: Using Mass Spectrometry to diagnose Prion diseases: Can we do that?**

**Dr. Christopher J. Silva**, U.S. Department of Agriculture, USA

08:20 - 08:40

**Title: The development of the use of generic products in Indonesia; does it increase or decrease and how is the role of bioequivalence study to ensure the quality of the products**

**Dr. Yahdiana Harahap**, University of Indonesia, Indonesia

08:40 - 09:00

**Title: Biocompatibility and Bioconditionality- A new mirror for current and future medicines**

**Dr. Wanbo Li**, China Beijing KLX Biosciences, Ltd. China

09:00 - 09:20

**Title: Bioequivalence study of Levofloxacin in healthy Kazakhs volunteers**

**Dr. Shnaukshta V.S.**, Medical Products and Equipment of the Ministry of Health, Republic of Kazakhstan

09:20 - 09:40 **Title: Solid phase analytical derivatization: an enabling technology for automation of ultra-high sensitivity HPLC and mass spectrometric methods**

**Dr. Jack Rosenfeld**, McMaster University, Canada

09:40 - 10:00 **Title: Synthesis and characterization of a new crystalline Pb(ii) selective composite cation exchange material Polyaniline Sn(iv) Molybdate: binary and ternary quantitative separations of toxic metal ions**

**Dr. Naushad Ghauri**, King Saud University, Saudi Arabia

10:00 - 10:20 **Title: Effect of multiple peak phenomena on bioequivalence results**

**Dr. Sima Sadrai**, Tehran University of Medical Sciences, Iran

10:20 - 10:40 **Title: Application of sub/supercritical fluid extraction as a new sample preparation procedure for isolation and identification of a pharmaceutical from biological fluids: Application to disposition kinetics**

**Dr. A. M. Abd El-Aty**, Cairo University, Egypt

**Coffee Break: 10:40-10:55**

**Track 3(iii): Design and Evaluation of BE Studies and Biosensing**

**Track 3(iv): Validation of a Sensitive LC-MS/MS Assay to Quantify the Biomarkers**

**Session Introduction**

10:55 - 11:15 **Title: Bioavailability by Design: Could we design nutrient absorption and metabolism for an improved benefit**

**Dr. Sunil Kochhar**, Nestle Reserach Center, Switzerland

11:15 - 11:35 **Title: Development and validation of an HPLC-ESI-MS/MS method for the quantitation of glucosamine in human plasma**

**Dr. Leonardo S. Teixeira**, ICF-Instituto de Ciencias Farmaceuticas, Brazil

11:35 - 11:55 **Title: Microanalysis of meropenem in biological fluids by UHPLC/MS using novel eluent components**

**Ms. Karin Kipper**, University of Tartu, Estonia

11:55 - 12:15 **Title: On bioequivalence metrics**

**Dr. Husam Awni Bayoud**, Fahad Bin Sultan University, Saudi Arabia

12:15 - 12:35 **Title: Quantification of Cyproheptadine in human plasma by high-performance liquid Chromatography coupled to electrospray tandem mass spectrometry in a bioequivalence study**

**Dr. Gustavo Duarte Mendes**, State University of Campinas, Brazil

12:35 - 12:55 **Title: Determination of flavonoid component change as defense materials against *Penicillium digitatum* employing LC/MS/MS**

**Dr. Jong Sung Jin**, Korea Basic Science Institute, Republic of Korea

**Lunch: 13:00-13:30**

**Track 7: Strategies and Challenges in Bioanalysis**

**Session Introduction**

13:30 - 13:50 **Title: Design of bioanalytical testing used in comparability studies for biosimilars**

**Dr. Dominique Gouty**, Intertek, USA

13:50 - 14:10 **Title: A simple LC/MS/MS method for safety assessments of metabolites**

**Dr. Hongying Gao**, Pfizer, Inc., USA

14:10 - 14:30 **Title: Screening of decitabine in combination with anti-cancer drugs for epigenetic synergy in a YB5 cell line**

**Dr. Taichun Qin**, University of Texas MD Anderson Cancer Center, USA

14:30 - 14:50 **Title: Bioequivalence assessment of Artesunate, a highly variable drug with bioactive metabolite, by using a new approach**

**Dr. Qigui Li**, Walter Reed Army Institute of Research, USA

14:50 - 15:10 **Title: The use of healthy volunteers to evaluate bioequivalence of antin-neoplastic drugs: pilot study with capecitabine**

**Dr. Gilberto De Nucci**, State University of Campinas, Brazil

15:10 - 15:30 **Title: Therapeutic monitoring of metformine in women with polycystic ovary syndrome**

**Dr. Naura Tonin**, Biocinese - Biopharmaceutical Studies Center, Brazil

**Coffee Break: 15:30-15:45**

15:45 - 16:05 **Title: Glycan microarrays for rapid analysis of functional glycomics**

**Dr. Injae Shin**, Yonsei University, Korea

16:05 - 16:25 **Title: Effect of fermentation on bioavailability of nutraceutical ingredients in functional products**

**Prof. S. M. Mousavi**, University of Tehran, Iran

16:25 - 16:45 **Title: Chitosan-graft-spermine as a gene carrier for lung cancer therapy**

**Dr. Myung-Haing Cho**, Seoul National University, Korea

16:45 - 17:05 **Title: Bioanalytical method development and validation for quantitation**

**Dr. Badraddin Alhadiya**, King Saud University, Saudi Arabia

17:05 - 17:25 **Title: Introducing sequential injection chromatography to biofluidic analysis**

**Dr. Abubakr M. Idris**, King Faisal University, Saudi Arabia

17:25 - 17:45 **Title: Microbial Concrete a wonder metabolic product improves the durability of building structures**

**Dr. Gustavo Duarte Mendes**, State University of Campinas, Brazil

### Rainbow Room

**Track 6(i): Pharmacokinetic Concepts in Drug Development**  
**Track 6(ii): Harmonization of BA/BE studies: Regulatory Aspects**

#### Session Introduction

08:00 - 08:20 **Title: Quantitative evaluation of bioequivalence/biosimilarity**

**Dr. Shein-Chung Chow**, Duke University School of Medicine, USA

08:20 - 08:40 **Title: The role of pharmacokinetic studies in development of drugs, containing endogenous compounds**

**Dr. Oleg Medvedev**, Lomonosov Moscow State University, Russia

08:40 - 09:00 **Title: Glycerophosphate is interchangeable with inorganic phosphate in terms of safety and serum pharmacokinetics**

**Dr. Christian Joukhadar**, J&P Medical Research Ltd., Austria

09:00 - 09:20 **Title: Recent trends in antihypertensives based on their pharmacokinetic parameters**

**Dr. Sanjita Das**, Noida Institute of Engineering and Technology, India

09:20 - 09:40 **Title: Cotinine, a tobacco- derived compound as a new drug to improve memory and reduce plaques in Alzheimer's disease**

**Dr. Valentina Echeverria**, Bay Pines VA Healthcare System, USA

09:40 - 10:00 **Title: Glipizide pharmacokinetics in healthy and diabetic volunteers**

**Dr. Muhammad Atif**, University Sains Malaysia, Malaysia

10:00 - 10:20 **Title: Validated LC-MS method for determination of Tamsulosin in human plasma and its application in bioequivalence study**

**Dr. Maricela Martinez-Delgado**, Dixpertia Investigacion Biofarmaceutica Farmacologica, Mexico

10:20 - 10:40 **Title: Bioavailability & bioequivalence: Pharmacokinetic principles**

**Dr. Abdus Samad**, Fortis Clinical Research Ltd, India

**Coffee Break: 10:40-10:55**

**Track 6(iii): BA/BE studies of Pharmacokinetic Drug Interactions**

#### Session Introduction

10:55 - 11:15 **Title: Novel approaches of bioavailability and bioequivalence studies**

**Dr. Barbara M. Davit**, Center for Drug Evaluation and Research-FDA, USA

11:15 - 11:35 **Title: Differences in Bioavailabilities (BA) determined using pharmacokinetic and pharmacodynamic parameters of endogenous compounds**

**Dr. Chyung S. Cook**, Baxter Healthcare, USA

11:35 - 11:55 **Title: Glycerophosphate does not interact with components of parenteral nutrition**

**Dr. Heinrich Topp**, Global Business Center, Germany

11:55 - 12:15 **Title: Bioavailability study of Zolmitriptan sublingual tablets on sheep model**

**Dr. Ziya BAYRAK**, Gulhane Military Medical Academy, Turkey

12:15 - 12:35 **Title: Modulation of bioavailability of anticancer drugs by drug interactions: An update**

**Dr. Sanjita Das**, Noida Institute of Engineering and Technology, India

12:35 - 12:55 **Title: LC-MS/MS determination of fosfomycin for a comparative bioavailability assay in healthy volunteers after a single dose administration**

**Dr. Fernando Torres-Roque**, Dixpertia Investigacion Biofarmaceutica y Farmacologica, Mexico

**Lunch: 13:00-13:30**

**Track 8(i): Biopharmaceutics and Formulation Development**  
**Track 8(ii): Role of PK/PD in Product Development**

#### Session Introduction

13:50 - 14:10 **Title: Risk assessment for oral bioavailability and bioequivalence during clinical formulation development**

**Dr. Henry Yunhui Wu**, Merck Research Laboratories, USA

14:10 - 14:30 **Title: PK/PD of Polymyxins against Gram-negative 'Superbugs'**

**Dr. Jian Li**, Monash University, Australia

14:30 - 14:50 **Title: Construction of a model for discriminating drugs with intestinal metabolism based on chemical structures and PK parameters**

**Dr. Yoshihiro Uesawa**, Meiji Pharmaceutical University, Japan

14:50 - 15:10 **Title: Advances in Pharmaceutical Sciences**

**Dr. Jayant Khandare**, Piramal Life Sciences Ltd, India

15:10 - 15:30 **Title: Comparative pharmacodynamics of Ceftobiprole, Daptomycin, Linezolid, Telavancin, Tigecycline, and Vancomycin in the treatment of Methicillin resistant Staphylococcus aureus: A Monte Carlo simulation analysis**

**Dr. Ayman M. Noreddin**, Hampton University, USA

**Coffee Break: 15:30-15:45**

## TBA Breakout Room

### Track 4-1: Anticancer, Antiviral, Antibacterial & Antifungal Drug Development

#### Session Introduction

08:00 - 08:20 **Title: Breast cancer is usually described as uncontrolled cellular growth however recent research suggests that is not accurate at least before primary surgery**

**Dr. Michael Retsky**, Harvard School of Public Health, USA

08:20 - 08:40 **Title: Extra cellular matrix derived endogenous angioinhibitors and their mechanism(s) of action**

**Dr. Sudhakar Akulapally**, Boys Town National Research Hospital, USA

08:40 - 09:00 **Title: Targeting of anticancer drugs using liquid core microcapsules via Radiotherapy**

**Dr. Satoshi Harada**, Iwate Medical University, Japan

09:00 - 09:20 **Title: A low molecular weight polysaccharide isolated from Agaricus blazei inhibits expression of E-selectin in activated endothelial cells and attenuates tumor cell adhesion**

**Dr. Ji-cheng Liu**, Qiqihar Medical University, China

09:20 - 09:40 **Title: Synthesis and anti-HCV activity evaluation of new anilincoumarin derivatives**

**Dr. Shyh-Chyun Yang**, Kaohsiung Medical University, Taiwan

09:40 - 10:00 **Title: Carica Papaya and Nicosan affect the pharmacokinetics of Ciprofloxacin in Rabbit**

**Dr. Grace E. Ukpo**, University of Lagos, Nigeria

10:00 - 10:20 **Title: Structure and function of a custom anticancer peptide**

**Dr. Hueih-Min CHEN**, National Nano Device Laboratories, Taiwan

10:20 - 10:40 **Title: Pharmacogenomics predictions for breast cancer treatments efficacy and toxicity**

**Dr. Hugo A. Barrera Saldana**, University of Nuevo Len, Mexico

**Coffee Break: 10:40-10:55**

10:55 - 11:15 **Title: Human Ecdysoles: A Novel Cellular Mediator of Oncogenesis**

**Dr. Channabasavaiah B Gurumurthy**, University of Nebraska Medical Center, USA

11:15 - 11:35 **Title: New biodegradable nanoparticle systems for the treatment of chronic lymphocytic leukemia and lymphomas**

**Dr. Eduardo Mansilla**, University of La Plata, Argentina

11:35 - 11:55

**Title: Study on interaction between cancer cells and mesenchymal stem cells via indirect or direct cell-to-cell connection**

**Dr. Xiaohui Long**, National Institute of Advanced Industrial Science and Technology (AIST), Japan

11:55 - 12:15

**Title: Discovery of anticancer agents-synthetic scaffolds**

**Dr. Umadevi Bhoga**, Inter-Mountain Labs, USA

12:15 - 12:35

**Title: Structural and functional analysis of human ERG oncoprotein: A potential target to develop the prostate cancer drug**

**Dr. Ajay K. Saxena**, Jawaharlal Nehru University, India

12:35 - 12:55

**Title: Investigation of the optimum condition and antimicrobial activities of pigments from four potent pigment-producing fungal species**

**Dr. Neveen S. Geweely**, Cairo University, Egypt

**Lunch: 13:00-13:30**

**Track 4(ii): Molecular Drug Target and Fragment Based Drug Design**

**Track 4(iii): Improving ADME/DMPK Profile**

**Track 4(v): Road Map to Drug Discovery and Development**

#### Session Introduction

13:30 - 13:50

**Title: Low-throughput drug screening approach designed to accelerate the development of new therapeutics for spinal cord injury**

**Dr. Pierre Guertin**, Laval University, Canada

13:50 - 14:10

**Title: Balancing physicochemical and ADME properties**

**Dr. Cornelis E.C.A. Hop**, Genentech, USA

14:10 - 14:30

**Title: ADME of a traditional Japanese (Kampo) medicine Daikenchuto (DKT)**

**Dr. Kazuhiro Hanazaki**, Kochi University, Japan

14:30 - 14:50

**Title: Towards in silico ADMET prediction based on three-dimensional models**

**Dr. Maria A. Miteva**, University Paris Diderot, France

14:50 - 15:10

**Title: Road map to drug discovery and development inhibiting C - reactive protein for the treatment of cardiovascular disease**

**Dr. Jan Torzewski**, Cardiovascular Center Oberallgau-Kempton, Deutschland

15:10 - 15:30

**Title: Indian medicinal plants Anona cherimola, Erythrina indica, Gymnema and Andrographis species - The best cure for diabetes**

**Dr. Anupalli Roja Rani**, Osmania University, India

15:30 - 15:50 **Title: Molecular modeling on protein targets related to metabolism and drug transport**

**Dr. Jose Correa Basurto**, National Polytechnic Institute, Mexico

**Coffee Break: 15:50-16:05**

**Track 5: PK/PD Models, Biowaivers and Biosimilars**

**Session Introduction**

16:05 - 16:25 **Title: The potential economic impact of Biosimilars in the United States**

**Dr. Joseph P. Fuhr**, Widener University, USA

16:25 - 16:45 **Title: 5-Cholesten-3beta, 25-diol 3-sulfate serves as a new medicine for therapy of hyperlipidemia**

**Dr. Shunlin Ren**, Virginia Commonwealth University, USA

16:45 - 17:05 **Title: Translating cellular science into human outcomes: a decade of experience with BCS-based Biowaivers**

**Dr. Sid Bhoopathy**, Absorption Systems, USA

17:05 - 17:25 **Title: Bioequivalence of highly variable drugs across countries**

**Dr. Laszlo Endrenyi**, University of Toronto, Canada

17:25 - 17:45 **Title: Quality from analytics and the strategy behind the physiochemical characterisation of biomolecules**

**Dr. Ashleigh Wake**, Intertek, USA

17:45 - 18:05 **Title: Detection of autosomal polycystic kidney disease using NMR Spectroscopy**

**Dr. Wolfram Gronwald**, University of Regensburg, Germany

18:05 - 18:25 **Title: Development of an integrated microscale ceramic separation device to address limited sample volumes in bioanalysis**

**Dr. Robert Plumb**, Waters Corporation, USA

18:25 - 18:45 **Title: An efficient kinase assay and a rapid screening of kinase inhibitors based on a biochip**

**Dr. Sang Hyun Park**, Korea Atomic Energy Research Institute, Korea

**Renaissance II & III Posters/B2B 08:00 - 17:00**

**8 June 11**

**Capital Room**

**Track 9: Practical Solutions to Pharmaceutical BA/BE Implementation**

**Session Introduction**

08:00 - 08:20 **Title: The role of modeling and simulations to better understand, optimize and predict bioequivalence**

**Dr. Murray P. Ducharme**, Cetero Research, USA & University of Montreal, Canada

08:20 - 08:40 **Title: Dissolution testing for generic drugs: An FDA perspective**

**Dr. Om Anand**, Food and Drug Administration, USA

08:40 - 09:00 **Title: Macromolecule-mediated chaperoning function in vivo and its implications in the protein aggregation-associated problems**

**Dr. Seongil Choi**, Yonsei University, South Korea

09:00 - 09:20 **Title: Harmonizing best practices in bioanalytical methods**

**Dr. Maha Tutunji**, University of Jordan, Jordan

09:20 - 09:40 **Title: Pre-clinical strategies to predict the bioavailability/bioequivalence studies**

**Dr. Joselia Larger Manfio**, Biocinese - Biopharmaceutical Studies Center, Brazil

09:40 - 10:00 **Title: Determination of interchangeability of different brands of metformin extended/sustained release tablets in healthy Indian male volunteers by regulatory defined bioequivalence criteria**

**Dr. Muzaffar Iqbal**, King Saud University, Saudi Arabia

10:00 - 10:20 **Title: Evaluation of the influence of obesity on the oral pharmacokinetics of Oseltamivir**

**Dr. Miriam del C. Carrasco**, National Institute of Respiratory Diseases Ismael Cosío Villegas, Mexico

10:20 - 10:40 **Title: GRAS combinations to alleviate presystemic metabolism**

**Dr. Phillip M. Gerk**, Virginia Commonwealth University, USA

**Coffee Break: 10:40-10:55**

**Track 10: Considerations for Conducting BA/BE Studies**

**Session Introduction**

10:55 - 11:15 **Title: Overview of Submission of Summary Bioequivalence Data for ANDAs**

**Dr. Ethan M Stier**, Food and Drug Administration, USA

11:15 - 11:35 **Title: Bioanalytical laboratory design; critical planning for 21st century bioequivalence laboratory**

**Dr. Naser L. Rezk**, KAIMRC, Saudi Arabia

11:35 - 11:55 **Title: Novel approach for the targeting of acidic tissue: pHLIP - pH (Low) insertion peptide**

**Dr. Yana K. Reshetnyak**, University of Rhode Island, USA

11:55 - 12:15 **Title: Scaled average bioequivalence statistics for the non-statistician**

**Charles Bon**, Biostudy Solutions, USA

12:15 - 12:35 **Title: SCN1A IVS5N+5 G>A polymorphism and response to drug treatment in epilepsy: A cohort study and a meta-analysis**  
**Dr. Batoul Sadat Haerian**, University of Malaya, Malaysia

12:35 - 12:55 **Title: Physiologically-relevant solubility and permeability screens in bioavailability and bioequivalence studies**  
**Dr. Noha Mohamed Zaki**, Ain Shams University, Egypt

**Lunch: 13:00-13:30**

#### Track 13(v): Topical Dermatological Drug Products

##### Session Introduction

13:30 - 13:50 **Title: Determination of the bioavailability of clobetasol propionate applied to the skin of human subjects using dermal microdialysis**  
**Prof. Isadore Kanfer**, Rhodes University, South Africa

13:50 - 14:10 **Title: Use of pharmacokinetics, pharmacodynamics and pharmacogenetics to optimize and assess bioavailability/bioequivalence of dermatopharmaceutical products**  
**Dr. Lynn Kennard Pershing**, RRI Group, Inc., USA

14:10 - 14:30 **Title: Validity of excised human skin as a model to establish the bioavailability and bioequivalence (BABE) of topical drug products**  
**Paul A. Lehman**, Cetero Research, USA

14:30 - 14:50 **Title: Challenges associated with determining the bioequivalence of veterinary topical drugs and possible technical solutions**  
**Dr. Ronald Baynes**, North Carolina State University, USA

14:50 - 15:10 **Title: An attempt for improving bioavailability and applications of phytoconstituents**  
**Dr. Mohan Singh**, Garhwal University, India

**Coffee Break: 15:10-15:25**

#### Rainbow Room

#### Track 11: Regulatory and Economical Aspects in BA/BE

##### Session Introduction

08:00 - 08:20 **Title: Graphical representation of the assessment of inventive step for patents using the problem-solution-approach (PSA)**  
**Dr. Joachim Stellmach**, European Patent Office, Germany

08:20 - 08:40 **Title: Regulatory and economical aspects of Bioavailability & Bioequivalence**  
**Zaidoon A. Al-Zubaidy**, RRI Group, Inc., USA

08:40 - 09:00 **Title: The impact of ethnic and racial differences on bioequivalence studies: The middle eastern experience**  
**Dr. Hisham S. Abou-Auda**, King Saud University, Saudi Arabia

09:00 - 09:20 **Title: A brief look at regulation changes over BA/BE, R&D studies in Turkey**  
**Dr. Barkin Berk**, Yeditepe University, Turkey

09:20 - 09:40 **Title: Safety monitoring boards and ethical committees for BA/BE studies**  
**Dr. Bhagirath Patel**, Gujarat University, India

#### Track 12: Novel Drug Delivery Systems

##### Session Introduction

09:40 - 10:00 **Title: Genetic approach to the construction of a controllable phage display platform for use in optimized therapeutic development**  
**Dr. Roderick A. Slavcev**, University of Waterloo, Canada

10:00 - 10:20 **Title: Production of drug-loaded nano- and microparticle formulations with ImSus Platform Technology**  
**Dr. Celal Albayrak**, Alrise Biosystems GmbH, Germany

10:20 - 10:40 **Title: Effect of cavitation intensity and lipid composition on physical properties of insulin-loaded tripalmitin & palmitic acid nanostructured lipid crystals (NLC)**  
**Dr. Nashiru Billa**, University of Nottingham-Malaysia Campus, Malaysia

**Coffee Break: 10:40-10:55**

10:55 - 11:15 **Title: Development of artificial therapeutic pulmonary surfactant to control oxidative stress in respiratory inflammation cases**  
**Mr. Apurva R. Shah**, Indian Institute of Technology-Bombay, India

11:15 - 11:35 **Title: Design and characterization of novel phytanyl substituted gemini surfactants for improved DNA transfection vectors**  
**Ms. Haitang Wang**, University of Waterloo, Canada

11:35 - 11:55 **Title: Thermoresponsive physical and chemical hydrogels in drug delivery**  
**Dr. Hossein Omidian**, Nova Southeastern University, USA

11:55 - 12:15 **Title: Preparation of bubble liposome: improved stability and ultrasound imaging**  
**Dr. Shafiqur Rahman**, The University of Queensland, Australia

12:15 - 12:35 **Title: Oral Abuse-Deterrent Formulations Using Physical Barriers**  
**David Mastropietro R**, Nova Southeastern University, USA

**Lunch: 13:00-13:30**

Track 13(i): Sustained Release Dosage Forms  
Track 13(iv): Pulmonary Drug Delivery Systems

Session Introduction

- 13:30 - 13:50 **Title: Role of CROs and Drug Delivery companies in product development**  
**Dr. Praveen S. Hiremath**, Pharmaceutics International Inc., USA
- 13:50 - 14:10 **Title: Bioequivalency study for inhaled drugs: A pharmacodynamic approach**  
**Dr. Luciana Fernandes Duarte**, Scentryphar Clinical Research, Brazil
- 14:10 - 14:30 **Title: Current global challenges in the bioequivalence of CR/MR and multiphasic formulations of drugs**  
**Dr. Murray P. Ducharme**, Cetero Research, USA & University of Montreal, Canada
- 14:30 - 14:50 **Title: Design and evaluation of polymeric ocular drug delivery system**  
**Dr. Vrushali Kashikar**, Govt. College of Pharmacy-Maharashtra, India
- 14:50 - 15:10 **Title: A new approach to bioequivalence studies for nasal sprays: Nasal challenge considering histamine intermediate-late phase reaction**  
**Ms. Natalia Eliza Zanellato Fabbri**, University of Campinas, Brazil
- 15:10 - 15:30 **Title: An anthology of various strategies to overcome the barriers of oral bioavailability**  
**Dr. Kanchan Kohli**, Jamia Hamdard University, India
- Coffee Break: 15:30-15:45**
- 15:45 - 16:05 **Title: Vesicular systems for intranasal drug delivery**  
**Dr. Ibrahim A. Alsarra**, King Saud University, Saudi Arabia
- 16:05 - 16:25 **Title: Deletion of a conserved LLRKXGXKG motif in Murine Hepatitis virus nonstructural protein 1 attenuates the virus in mice**  
**Dr. Chang Guohui**, Academy of Military Medical sciences, China
- 16:25 - 16:45 **Title: Mimovirus: a novel form of vaccine induced specific cytotoxic T lymphocyte responses in vivo**  
**Dr. Yu-Zhang Wu**, Third Military Medical University, P.R. China
- 16:45 - 17:05 **Title: Cigarette smoke effects on autonomic regulation of cardiovascular system: Studies in human and animals**  
**Dr. Vitor Engracia Valenti**, Federal University of Sao Paulo, Brazil
- 17:05 - 17:25 **Title: Nanosuspensions: An enhanced bioavailability of pulmonary drug deliver**  
**Dr. K. Vijaya Sri**, Malla Reddy College of Pharmacy, India

17:25 - 17:45

**Title: Single dose relative bioavailability and safety of a new Quetiapine fumarate extended release formulation: Is there a food effect on XR performance**

**Dr. Francisco E. Estevez-Carrizo**, University of Montevideo Center of Biomedical Sciences, Uruguay

Rennissance II & III

Track 13(ii): Targeted Drug Delivery Systems

Track 13(iii): Transdermal Drug Delivery Systems

Session Introduction

08:00 - 08:20

**Title: Tetracycline serum compatible gene delivery system**

**Dr. Peisheng Xu**, University of South Carolina, USA

08:20 - 08:40

**Title: Using living cells for targeted drug transport across blood brain barrier**

**Dr. Elena V. Batrakova**, Center for Drug Delivery and Nanomedicine, USA

08:40 - 09:00

**Title: Technology-based pharmaceutical drug delivery: Shifting paradigm**

**Dr. Shivanand P. Puthli**, Panacea Biotec Ltd., India

09:00 - 09:20

**Title: Non-invasive magnetic resonance imaging as a novel tool to readout functional properties of analgesic drugs in pain research**

**Dr. Andreas Hess**, Friedrich Alexander University Erlangen-Nuremberg, Germany

09:20 - 09:40

**Title: Outcome of nanostructured transdermal bioidentical hormone therapy for patients with climacteric syndrome**

**Dr. Marco Antonio Botelho**, Potiguar University School of Health, Brazil

09:40 - 10:00

**Title: Evolution of ex vivo drug sensitivity from Plasmodium falciparum-infected senegalese patients using a new assay**

**Dr. Daouda NDIAYE**, Cheikh Anta Diop University, Senegal

10:00 - 10:20

**Title: Nanosized drug delivery systems: In recent years**

**Dr. Rawia Khalil**, National Research Center, Egypt

**Coffee Break: 10:40-10:55**

Rennissance II & III B2B 10:40 - 15:00